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Abstract 
OBJECTIVE: To report a case of sudden cardiac death in a patient taking a combination of cloza-
pine and lorazepam. CASE SUMMARY: A 31-year-old white man with schizophrenia was found dead at his 
apartment. His medication regimen included clozapine 500 mg at bed time, lorazepam 0.5 mg three times 
daily and levothyroxine 75 mcg once a day. Autopsy studies revealed cardiac hypertrophy, pulmonary con-
gestion and edema. DISCUSSION: Clozapine therapy may cause cardiomyopathy and reduction in heart 
rate variability (HRV) indices. Benzodiazepines can reduce vagal tone and increase sympathetic activity. 
This combination can have an enhanced potential for sudden cardiac death. CONCLUSIONS: Clozapine-
induced cardiomyopathy and arrhythmias from clozapine and/or lorazepam use may have contributed to this 
man's death. 
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Introduction 
Sudden cardiac death (SCD) is defined as an unexpected death due to cardiac causes, occurring in a short 
span of time, generally within one hour of symptom onset in a person with known or unknown cardiac dis-
ease with no previously diagnosed fatal condition. 
Epidemiological studies of schizophrenic patients suggest an increased incidence of cardiovascular mortal-
ity (1,2), which has been linked to the use of antipsychotic medications (3,4). It is well established that some 
antipsychotic drugs prolong the QT interval, and cause torsades de pointes (5). An increased risk of sudden 
cardiac death may be related to the dose-related effects of antipsychotic medications on cardiac electrophys-
iology. We report a case of presumed sudden cardiac death in a middle-aged male possibly due to the com-
bination of clozapine and lorazepam. 
Case report 
Patient A was a 31-year-old Caucasian male with a diagnosis of schizophrenia, undifferentiated type based 
on DSM-IV criteria. He had a history of multiple psychiatric hospitalizations due to non-compliance with 
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medications. Prior to admission, the patient was receiving olanzapine 15 mg twice a day, haloperidol 10 mg 
at bedtime, lorazepam 0.5 mg three times a day and benztropine mesylate lmg three times a day. He was 
also on levothyroxine 75 mcg once a day for recently diagnosed hypothyroidism. In addition, he had a his-
tory of hypertension, which was not being treated because his blood pressure was within normal limits. His 
laboratory workup was essentially normal. No electrocardiogram was done during the admission. His fam-
ily history was negative for cardiovascular disease or sudden death. The patient admitted to occasional 
cannabis use and there was no history of alcohol use. 
It was observed during an outpatient appointment that the patient continued to show signs of psychosis. He 
was then switched from olanzapine to risperidone, but his symptoms persisted. Therefore, clozapine 50 mg 
at bedtime was initiated after obtaining consent and following relevant medical workup. The dose of cloza-
pine was gradually titrated to 500 mg at bedtime; risperidone and haloperidol were discontinued, while 
lorazepam 0.5 mg three times a day, and levothyroxine 75 mcg once daily were continued. With this combi-
nation of medications administered under supervision of his case manager, the patient did well. He showed 
decreased aggression and improved organization of speech and thought process. However, he continued to 
exhibit some social withdrawal. The patient was prescribed clozapine for approximately one year. Clozapine 
levels obtained at regular intervals were within the recommended range for optimal clinical response (6). The 
CBC with differential, done at suggested intervals, was within normal limits. (See Table 1) 
Table 1 
Serial Clozapine and Norclozapine Levels 
CLOZAPINE NORCLOZAPINE COMBINED 
139 ng/L 162 ng/L 310 ng/1 
246ng/L 132 ng/L 378ng/L 
175ng/L 172ng/L 347 ng/L 
173ng/L 14Ong/L 313 ng/L 
During routine follow up home visits on two successive days by his caseworker, the patient failed to answer 
the doorbell. The door was forcibly opened; the patient was found lying slumped in a chair and was unre-
sponsive. Emergency Medical Services was called and the patient was declared dead. A day's supply of his 
medications was found near the entry door. 
The post-mortem toxicology studies were negative for amphetamines, cocaine, cannabis, benzodiazepines, 
methadone, opiates, phencyclidine, propoxyphene and barbiturates. The blood ethanol level was less than 
0.010 g/100m1. The blood immunoassay detected clozapine and nicotine; both blood clozapine and norcloza-
pine concentrations were less than 100 ng/ml each. 
Gross autopsy findings showed a middle-aged male measuring 69.5 inches in length, 250 pounds in weight. 
There was no evidence of trauma nor epidural, subdural or intracranial hemorrhage. There were no foreign 
bodies in the larynx or in the tracheobronchial tree and no pills or capsule fragments were identified in the 
stomach contents. 
There was cardiac hypertrophy, with the heart weighing 480 grams (normal being up to 375 grams). The free 
wall of the left ventricle and the interventricular septum measured 15 mm in thickness (normal 10mm). The 
right ventricular wall measured 4 mm in thickness (normal 10 mm). There was moderate dilatation of all four 
chambers of heart. Final anatomic diagnoses were: 1) cardiac hypertrophy, 2) coronary atherosclerosis with 
0-25% narrowing of the left anterior descending coronary artery, 3) moderate four chamber dilatation of 
heart, 4) pulmonary congestion and edema, 5) benign cortical cyst left kidney, 6) congestion of abdominal 
viscera. The final cause of death was hypertensive heart disease with the terminal event most likely being an 
acute cardiac arrhythmia. 
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Discussion 
Clozapine, a tricyclic dibenzodiazepine derivative, is classified as an atypical antipsychotic. It is indicated 
for the management of treatment resistant, severely ill schizophrenic patients. Benefits of clozapine include 
lack of extrapyramidal side effects and the reduction of negative symptoms (7). A rare side effect of don-
azapine is agranulocytosis, with a rate of 1.3% (8). Well-documented cardiovascular effects of clozapine 
include orthostatic hypotension (9%), tachycardia (25%) and electrocardiogram changes (1%) (8). 
New onset EKG changes consisting of premature ventricular contractions have been reported with clozap-
ine therapy (9). Clozapine has been demonstrated to cause concentration dependent prolongation of the QT 
interval in isolated feline hearts (10). The data suggest that clozapine may also have proarrhythmic activity 
and could potentially give rise to life threatening arrhythmias particularly with overdose, either directly or 
in combination with a coexisting myocarditis. The low postmortem clozapine concentration in our patient 
could be explained by the missed doses of clozapine found in the patient's apartment. However, the blood 
clozapine levels done at serial intervals and also the one closest to the time of his death (within a month) 
were therapeutic. Medication compliance was also ensured by supervised administration of his medications. 
Most sudden cardiac death is attributed to ventricular tachycardia and or ventricular fibrillation with the 
autonomic nervous system playing an important role. One reliable measure quantifying autonomic nervous 
system activity is the heart rate variability (HRV) (11). In one study, clozapine was shown to disrupt auto-
nomic neurocardiac function by reducing HRV in seven out of 13 patients receiving the drug (12). Reduced 
HRV has been shown to increase the risk of sudden death (13). In our patient we did not have an EKG or 24 
hour Holter monitoring to substantiate this cause. 
Lorazepam may have significant vagolytic effects as manifested by the increase in heart rate and decreases 
in HPV (heart period variability indices), as demonstrated by a double blind randomized placebo controlled 
study in healthy volunteers (14). Another study examining the short-term effects of intravenous application 
of benzodiazepines suggested that they cause a reduction of central vagal tone. They may also decrease the 
cardiac pacemaker activity directly (15). The likely mechanism through which benzodiazepines produce 
vagolytic effects is probably through their interaction with the gamma-aminobutyric acid A-receptor chlo-
ride ion channel complex (16). An imbalance in cardiac sympathetic autonomic tone in favor of high sym-
pathetic activity increases the risk for cardiac morbidity or mortality in patients with preexisting cardiac dis-
ease (17), even in patients without structural heart disease (18). 
The effects of the combination of antipsychotics and benzodiazepines on the autonomic neurocardiac func-
tion (ANR) have not yet been systematically investigated. Furthermore, it is not known whether the combi-
nation of an antipsychotic and a benzodiazepine increases the risk for cardiac arrhythmias and sudden death, 
as compared to the risks associated with the individual agents. It is possible in the case presented, that cloza-
pine and lorazepam caused his death. This theory would be supported if an autopsy showed pathological car-
diac findings or left ventricular and interventricular septal hypertrophy. In our case, the patient was found 
to have left ventricular hypertrophy, making it plausible that the combination of clozapine and lorazepam 
caused his death. It cannot be ignored that our patient was diagnosed with hypertension. However, he was 
normotensive prior to his death, and therefore, not taking any antihypertensive medication. Furthermore, 
studies have shown that there is no correlation of LVH in individuals with normal blood pressure versus ele-
vated blood pressure in patients younger than 65 (19). 
A literature search on MEDLINE from 1966 through 2002 showed case reports of sudden death in patients 
treated concurrently with clozapine and benzodiazepine (20), clozapine and haloperidol (21) and clozapine 
and sertraline (22). The case report with clozapine and sertraline (22) was attributed to clozapine induced 
cardiomyopathy without evidence of myocarditis. This search revealed no reports of sudden death with 
lorazepam monotherapy. Clozapine is metabolized by the cytochrome enzyme system; CYP 450 1A2, 2C19 
and 34A (8). Lorazepam is metabolized via the glucuronidation pathway, so there is no major drug interac-
tion between the two drugs via the CYP-450 system. Two cases have been reported in which concomitant 
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use of clozapine and lorazepam resulted in marked sedation, excessive salivation, and ataxia (23), and cau-
tion is advised when administering clozapine with a benzodiazepine (8). In the case report where there was 
sudden death after intravenous administration of lorazepam to a patient treated with clozapine, the autopsy 
did not show any pathological findings and the death was presumed due to respiratory failure. 
Our patient was taking lorazepam and clozapine at the time of death and the autopsy showed evidence of 
cardiomegaly. Use of the Naranjo ADR Probability Scale (24) indicated a possible relationship between sud-
den cardiac death and combined therapy with lorazepam and clozapine in this patient. To our knowledge this 
is the first report of sudden cardiac death in a patient treated with a combination of clozapine and lorazepam 
with pathological autopsy findings. 
Summary 
This case report is not conclusive in proving a direct relationship between combined clozapine and 
lorazepam use and sudden death. However it points in that direction. There is evidence to suggest that cloza-
pine therapy may cause cardiomyopathy, myocarditis, and reduction in heart rate variability (HRV) indices 
as well as anticholinergic effects resulting in proarrthymogenic outcomes. Moreover benzodiazepines can 
cause reduction in vagal tone with subsequent shifting of neurocardiac balance in favor of sympathetic activ-
ity. This effect can enhance potential for cardiac death in a patient taking a combination of clozapine and 
lorazepam. There may be other unexplained effects of this combination leading to this fatal complication. In 
any case, it is important that the prescribing clinicians be aware of the potential for a sudden cardiac death 
with the combination of clozapine and lorazepam therapy. 
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